Secreted Clusterin gene silencing enhances chemosensitivity of A549 cells to cisplatin through AKT and ERK1/2 pathways in vitro

Cellular Physiology and Biochemistry

Volumn 33, Issue 4, 2014, Pages 1162-1175

  Zhang, Biyuan ^a   Zhang, Kejun ^b   Liu, Zimin ^a   Hao, Fengyun ^c   Wang, Mei ^d,e   Li, Xiangchun ^a,e   Yin, Zongsiu ^a,e   Liang, Hui ^f  

^a Internal Medicine Oncology   (China)

^b Department of Liver and Vascular   (China)

^c Pathology ^*  (China)

^d QINGDAO UNIVERSITY   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f Qingdao Women and Children Health Care Centers   (China)

Author keywords

AKT; Chemotherapy; Cisplatin; Clusterin; ERK1 2; Lung cancer

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CISPLATIN; CLUSTERIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SHORT HAIRPIN RNA; WORTMANNIN; 1,3 BUTADIENE DERIVATIVE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; NITRILE; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CORRELATIONAL STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE; A549 CELL LINE; CONTROLLED STUDY; ENZYME INACTIVATION; LUNG CANCER;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BUTADIENES; CELL LINE, TUMOR; CISPLATIN; CLUSTERIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84898674387     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358685     Document Type: Article

References (58)

1. Spira A, Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.
2. Neal JW, Gubens MA, Wakelee HA: Current management of small cell lung cancer. Clin Chest Med 2011;32:853-863.
3. Chang A: Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
4. Kartalou M, Essigmann JM: Mechanisms of resistance to cisplatin. Mutat Res 2001;478:23-43.
5. Rabik CA, Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007;33:9-23.
6. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
7. Rosenberg ME, Silkensen J:Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 1995;27:633-645.
8. Jones SE, Jomary C: Clusterin. Int J Biochem Cell Biol 2002;34:427-431.
9. Niu ZH, Wang Y, Chun B, Li CX, Wu L: Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur Rev Med Pharmacol Sci 2013;17:1337-1344.
10. Zoubeidi A, Chi K, Gleave M: Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer.Clin Cancer Res 2010;16:1088-1093.
11. Yang GF, Li XM, Xie D: Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int J Gynecol Cancer 2009;19:1342-1346.
12. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Zhang LJ, Guan XY, Zeng YX, Xie D: Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci 2009;100:2354-2360.
13. Xie MJ, Motoo Y, Su SB, Mouri H, Ohtsubo K, Matsubara F, Sawabu N: Expression of clusterin in human pancreatic cancer. Pancreas 2002;25:234-238.
14. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK: Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 2008;10:964-972.
15. Wang Y, Wang X, Zhao H, Liang B, Du Q: Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. J Chemother 2012;24:348-357.
16. Chou TY, Chen WC, Lee AC, Hung SM, Shih NY, Chen MY: Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. Cell Signal 2009;21:704-711.
17. Yan Y, Luo K, Zhang H, Chai W: RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells. Hepatogastroenterology 2013;60:70-75.
18. Cheng CY, Cherng SH, Wu WJ, Yang TY, Huang XY, Liao FT, Wu MF, Sheu GT: Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells. Cancer Chemother Pharmacol 2012;69:145-154.
19. Laskin JJ, Nicholas G, Lee C, Gitlitz B, Vincent M, Cormier Y, Stephenson J, Ung Y, Sanborn R, Pressnail B, Nugent F, Nemunaitis J, Gleave ME, Murray N, Hao D: Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol 2012;7:579-586.
20. Cao C, Shinohara ET, Li H, Niermann KJ, Kim KW, Sekhar KR, Gleave M, Freeman M, Lu B: Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int J Radiat Oncol Biol Phys 2005;63:1228-1236.
21. Kapoor S: Clusterin inhibition to enhance tumor chemosensitivity in systemic tumors. Cancer Chemother Pharmacol 2013;71:1101.
22. Bortul R, Tazzari PL, Billi AM, Tabellini G, Mantovani I, Cappellini A, Grafone T, Martinelli G, Conte R, Martelli AM, Deguelin A: PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway. Br J Haematol 2005;129:677-686.
23. Liu D, Zhang Y, Dang C, Ma Q, Lee W, Chen W: siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway. Oncol Rep 2007;18:673-677.
24. Guinea Viniegra J, Hernández Losa J, Sánchez-Arévalo VJ, Parada Cobo C, Fernández Soria VM, Ramón y Cajal S, Sánchez-Prieto R: Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin. Oncogene 2002;21:7131-7136.
25. McCubrey JA, Steelman LS, Abrams SL: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-279.
26. McCubrey JA, Steelman LS, Chappell WH: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-1284.
27. Sridhar SS, Hedley D, Siu LL: Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4:677-685.
28. Tang Y, Liu F, Zheng C, Sun S, Jiang Y: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res 2012;31:73.
29. Si H, Peng C, Li J, Wang X, Zhai L, Li X, Li J: RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and invasion and increases chemosensitivity to cisplatin in human osteosarcoma U2-OS cells in vitro. Int J Oncol 2012;40:1291-1297.
30. Zhou L, Luan H, Liu Q, Jiang T, Liang H, Dong X, Shang H: Activation of PI3K/Akt and ERK signaling pathways antagonized sinomenine-induced lung cancer cell apoptosis. Mol Med Rep 2012;5:1256-1260.
31. Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C: Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 2011;56:275-284.
32. Lee HY, Oh SH, Suh YA, Baek JH, Papadimitrakopoulou V, Huang S, Hong WK: Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt-and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer. Clin Cancer Res 2005;11:6065-6074.
33. Wang M, Liu ZM, Li XC, Yao YT, Yin ZX: Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells. J Chemother 2013;25:162-169.
34. Li J, Jia L, Zhao P, Jiang Y, Zhong S, Chen D: Stable knockdown of clusterin by vector based RNA interference in a human breast cancer cell line inhibits tumour cell invasion and metastasis. J Int Med Res 2012;40:545-555.
35. Xiu P, Dong X, Dong X, Xu Z, Zhu H, Liu F, Wei Z, Zhai B, Kanwar JR, Jiang H, Li J, Sun X: Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer Sci 2013;104:375-382.
36. Ma X, Bai Y: IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin. Mol Med Rep 2012;6:1433-1437.
37. Scaltriti M, Bettuzzi S, Sharrard RM, Caporali A, Caccamo AE, Maitland NJ: Clusterin in both malignant and nonmalignant prostate epithelial cells induces cell cycle arrest and apoptosis. Br J Cancer 2004;91:1842-1850.
38. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, Perego P: Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 2003;3:21-29.
39. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003;22:7265-7279.
40. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
41. Springate CM, Jackson JK, Gleave ME, Burt HM: Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models. Cancer Chemother Pharmacol 2005;56:239-247.
42. Miyake H, Hara S, Zellweger T, Kamidono S, Gleave ME, Hara I: Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells. Mol Urol 2001;5:105-111.
43. Hoeller C, Pratscher B, Thallinger C, Winter D, Fink D, Kovacic B, Sexl V, Wacheck V, Gleave ME, Pehamberger H, Jansen B: Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol 2005;124:1300-1307.
44. Redondo M, Téllez T, Roldan MJ, Serrano A, García-Aranda M, Gleave ME, Hortas ML, Morell M: Anticlusterin treatment of breast cancer cells increases the sensitivities of chemotherapy and tamoxifen and counteracts the inhibitory action of dexamethasone on chemotherapy-induced cytotoxicity. Breast Cancer Res 2007;9:R86.
45. Lourda M, Trougakos IP, Gonos ES: Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int J Cancer 2007;120:611-622.
46. Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA, Uslu R: Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep 2013;40:3925-3933.
47. Pajak B, Orzechowski A: Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line. Anticancer Drugs 2007;18:55-63.
48. Peyssonnaux C, Eychène A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001;93:53-62.
49. Zhuang S, Schnellmann RG: A death-promoting role for extracellular signal-regulated kinase. J Pharmacol Exp Ther 2006;319:991-997.
50. Ko JC, Tsai MS, Chiu YF, Weng SH, Kuo YH, Lin YW: Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells. J Pharmacol Exp Ther 2011;338:184-194.
51. Gozdz A, Habas A, Jaworski J, Zielinska M, Albrecht J, Chlystun M, Jalili A, Hetman M: Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. J Biol Chem 2003;278:43663-43671.
52. Huang WC, Hung MC: Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 2009;108:180-194.
53. Seo JH, Jeong ES, Lee KS, Heo SH, Jeong DG, Choi YK: Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil. Int J Oncol 2013;43:2007-2014.
54. Heavey S, O'Byrne KJ, Gately K: Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat Rev 2013:S0305-7372:00171-00180.
55. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, Ashendel C, Zalkow L, Matter WF, Dodge J, Grindey G: Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res 1994;54:2419-2423.
56. Yao R, Cooper GM: Requirement for phosphatidylinositol 3-kinase in the prevention of apoptosis by nerve growth factor. Nature (Lond) 1995;267:2003-2006.
57. Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM: Serine/threonine protein kinases and apoptosis. Exp Cell Res 2000;256:34-41.
58. Cobb MH: MAP kinase pathways. Prog Biophys Mol Biol 1999;71:479-500.